Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Half-normal saline Clear all
Terminated Phase 2 Interventional Results available

A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain

NCT00414466
View directory record Official record
Conditions
Chronic Intractable Pain
Interventions
Intraspinal Gabapentin
Drug
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years to 70 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
14
States / cities
Little Rock, Arkansas • Napa, California • Sarasota, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Sep 21, 2026, 10:58 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline

NCT02115256
View directory record Official record
Conditions
External Cephalic Version
Interventions
Intravenous Terbutaline, Intravenous Nitroglycerine
Drug
Lead sponsor
Yaakov Beilin
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis

NCT03705793
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Allergic Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis
Interventions
Mometasone Furoate Nasal Irrigation, Mometasone Nasal Spray
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

NCT05330078
View directory record Official record
Conditions
Keloid
Interventions
Botulinum toxin type A, Vehicle
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 21, 2026, 10:58 AM EDT
Withdrawn Early Phase 1 Interventional

Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study

NCT06345833
View directory record Official record
Conditions
Hemophilia, Hemorrhage, Facelift Surgery
Interventions
1%Tranexamic acid with standard local, 3% TXA, 1% TXA with local plus 3% TXA-soaked pledgets
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation

NCT03647917
View directory record Official record
Conditions
Skin Aging of Face and Hands
Interventions
Platelet Rich Plasma
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

NCT01409915
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Sagramostim, Saline -- placebo comparator
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 21, 2026, 10:58 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Restylane Silk for Treatment of Chest Wrinkles

NCT03324997
View directory record Official record
Conditions
Wrinkle
Interventions
Restylane Silk, Saline, Optical Coherence Tomography
Drug · Device
Lead sponsor
Heidi Waldorf
Other
Eligibility
25 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

NCT05285137
View directory record Official record
Conditions
Healthy
Interventions
CD388 Injection, Saline placebo
Combination Product · Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 21, 2026, 10:58 AM EDT
Terminated Phase 4 Interventional Results available

IV Lidocaine in Pediatric AIS

NCT03893318
View directory record Official record
Conditions
Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery
Interventions
IV lidocaine, Placebos
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 21, 2026, 10:58 AM EDT
Not yet recruiting Phase 4 Interventional

Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)

NCT07424378
View directory record Official record
Conditions
Frostbite
Interventions
Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum, Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treat COVID-19 Patients With Regadenoson

NCT04606069
View directory record Official record
Conditions
COVID-19, Lung Inflammation
Interventions
Regadenoson, Placebo Control
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Results available

Does Preop Midazolam Maintain Blood Glucose Norms in the Non Diabetic Perioperative Period

NCT01641653
View directory record Official record
Conditions
Hernia
Interventions
Normal saline, Midazolam
Other · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

NCT05525546
View directory record Official record
Conditions
Risk Reduction
Interventions
Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 21, 2026, 10:58 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Pilot Study of Magnesium Infusions in Pediatric Asthma

NCT01522040
View directory record Official record
Conditions
Asthma
Interventions
Magnesium Sulfate, Placebo
Drug
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Results available

Study of EXPAREL in Patients Undergoing Breast Augmentation

NCT01582490
View directory record Official record
Conditions
Mammoplasty, Postoperative Pain
Interventions
Instillation - EXPAREL, Infiltration - EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Not applicable Interventional

Adductor Canal Blocks With Bupivacaine and Magnesium After Same-day Discharge Total Knee Arthroplasty Improve Post-operative Pain Relief and Decrease Opioid Consumption: a Prospective Randomized Controlled Trial

NCT05004636
View directory record Official record
Conditions
Post-operative Pain, Acute
Interventions
Adding Magnesium as an adjuvant to the adductor canal Block (ACB) for same-day discharge total knee arthroplasty
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Not applicable Interventional

Half-normal Saline in Atrial Fibrillation Ablation

NCT03498586
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Half-normal saline, Normal saline
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 21, 2026, 10:58 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Prospective Randomized Double Blinded Controlled Trial of Non-Operative Management of TFCC Injuries

NCT03830775
View directory record Official record
Conditions
Wrist Injuries, PRP
Interventions
Platelet-rich plasma (PRP)
Procedure
Lead sponsor
Edna Rath
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid

NCT01707069
View directory record Official record
Conditions
Allergic Rhinoconjunctivitis
Interventions
CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
Biological
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome

NCT01941745
View directory record Official record
Conditions
Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions
Half normal saline, Low Dose rhCC10, High dose rhCC10
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
24 Weeks to 29 Weeks
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

NCT05777174
View directory record Official record
Conditions
Kidney Diseases, Kidney Injury, Kidney Failure
Interventions
MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Columbus, Ohio • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 21, 2026, 10:58 AM EDT
Not yet recruiting Not applicable Interventional

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

NCT07254650
View directory record Official record
Conditions
Lung Cancer (Diagnosis)
Interventions
Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 21, 2026, 10:58 AM EDT